Racial differences in the androgen/androgen receptor pathway in prostate cancer

Journal of the National Medical Association

Volumn 91, Issue 12, 1999, Pages 653-660

  Pettaway, Curtis A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Androgen receptor; Prostate cancer; Race; Serum hormone levels

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

BLOOD; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; MALE; METABOLISM; NEGRO; PROSTATE TUMOR; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANDROGENS; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSCRIPTION, GENETIC;

EID: 0033252881     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Landis SH, Murray J, Bolden S, Wingo PA. Cancer Statistics. 1999;49:8-31.
2. Pienta KJ. Etiology, epidemiology, and prevention of carcinoma of the prostate. In: Walsh PC, Retik AB, Vaughn ED, Wein AJ. Campbell's Urology. 7th ed. Philadelphia, PA: WB Saunders Co; 1998:2489-2496.
3. Mebane C, Gibbs T, Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc. 1990;82: 782-788.
4. Sakr WA, Grignon DJ, Haas GP, et al. Epidemiology of high grade prostate intraepithelial neoplasia. Pathol Res Pract. 1995; 191:838-841.
5. Wilson JD. Syndromes of androgen resistance. Biol Reprod. 1992;46:168-173.
6. Montie JE, Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology. 1994;43:892-899.
7. McCormell JD. 5α-reductase inhibitor therapy: limitations and advances. In: Stamey TA, ed. Monographs in Urology. Monteverde, FL: Medical Directions Publishing Co; 1997:105-119.
8. Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD, Russell DW. Cell type specific expression of steroid 5α-reductase 2. J Urol. 1994;152:438-442.
9. Young CYF, Montgomery BT, Andrews PE, Qiu S, Bilhartz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. 1991;51:3748-3752.
10. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977;37:1929-1933.
11. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol. 1993;7:1541-1550.
12. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990;126:1165-1172.
13. O'Malley BW, Tsai M-J. Molecular pathways of steroid receptor action. Biol Reprod. 1992;46:163-167.
14. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest. 1993;92: 903-910.
15. Ghanadian R, Puah CM, O'Donoghue EPN. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer. 1979;39:696-699.
16. Ahluwalia B, Jackson MA, Jones GW, Williams AO, Mamidanna SR, Rajguru S. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer. 1981;48:2267-2273.
17. Osegbe DN, Ogunlewe JO. Androgen concentration in blacks with benign and malignant prostatic disease. J Urol. 1988; 146:160-164.
18. dejong FH, Oishi K, Hayes RB, et al. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostate hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res. 1991;51:3445-3550.
19. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res. 1988;48:3515-3517.
20. Barrett-Connor E, Garland C, McPhillips JB, Khaw K, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990;50:169-173.
21. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993;2:27-32.
22. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer. 1988;57:216-218.
23. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76:45-48.
24. Ellis L, Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids. 1992;57:72-75.
25. Ross RK, Bernstein L, Lobo RA, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887-889.
26. Lookinbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endrocrinol Metal. 1991;72:1242-1248.
27. Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995;55: 3973-3975.
28. Makridakis N, Ross R, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 1997;57:1020-1022.
29. Brown TR. Provocative aspects of androgen genetics. Prostate. 1996;6:9-12.
30. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA. 1992;89:6319-6323.
31. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutations in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994;54:2861-2864.
32. Brawn PN, Johnson EH, Kuhl DL, et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer. 1993;71:2569-2573.
33. Optenberg SC, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal access medical care delivery system. JAMA. 1995;274:1599-1605.
34. Fowler JE, Bigler SA, Renfroe DL, Dabagia MD. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. J Urol 1997;158:150-154.
35. Takahashi H, Furusato M, Allsbrook WC, Nishii H, Wakui S, Barrett C. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res. 1995;55:1621-1624.
36. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer: comparison of receptor content and response to hormonal therapy. Cancer. 1991;67:3057-3064.
37. Sadi MV, Barrack EV. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer. 1993; 71:2574-2580.
38. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeats loci in four human population groups. Genomics. 1992;12: 241-253.
39. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER. Androgen receptor variants with short glutamine and glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res. 1997;3:1599-1608.
40. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3181-3186.
41. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995;55: 1937-1940.
42. Giovannucci E, Stampfer M, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 1997;94:3320-3323.
43. Partin AW, OesterlingJE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994;152:1358-1368.
44. Babaian RJ, Troncoso P, Steelhammer LC, Loreta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 1995;154:1808-1812.
45. Pettaway CA, Pathak S, Green G, et al. Selection of highly metastatic variants of human prostatic carcinomas (PC-3M, LNCaP) utilizing orthotopic implantation in nude mice. Clin Cancer Res. 1996;2:1627-1636.
46. Hsieh JT, Wu HC, Cleave ME, von Eschenbach AC, Chung LWK. Autocrine regulation of prostate specific antigen gene expression in a human prostate cancer (LNCaP) cell line. Cancer Res. 1993;53:2852-2857.
47. Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AM. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992;1:541-545.
48. Moul JD, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277-1281.
49. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobsen DJ, McLeod DG, Moul JW. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med. 1996;335: 304-310.
50. Oesterling JE, Kumamoto Y, Tsukamoto T, et al. Serum prostate specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol. 1995;75:347-353.
51. Powell IJ, Heilbrun LK, Sakr W, et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins. Urology. 1997;49:726-731.
52. Henderson RJ, Eastham JA, Culkin DJ, et al. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997;89:134-138.
53. Pettaway CA, Troncoso P, Ramirez EI, Johnston D, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol 1998; 160:437-442.
54. Vijayakumar S, Quadri SF, Dong L, et al. Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J Natl Med Assoc. 1995;87:813-819.